AbbVie Sues US Government Over Botox Medicare Price Negotiations

AbbVie Inc. has filed a lawsuit against the U.S. Department of Health and Human Services (HHS), challenging the inclusion of its blockbuster drug, Botox, in the Medicare drug price negotiation program. The pharmaceutical giant's legal action targets a key provision of the Inflation Reduction Act (IRA), which aims to lower prescription drug costs for Medicare beneficiaries. This move signals a significant dispute over the future pricing of essential medications, potentially impacting AbbVie's revenue streams. Analysts suggest the lawsuit introduces uncertainty regarding the company's financial outlook, particularly concerning the profitability of key products like Botox. The challenge underscores the ongoing tension between pharmaceutical companies and the U.S. government's efforts to contain healthcare expenditures. This legal battle could set a precedent for future drug pricing disputes within the industry.